Pharmacokinetic evaluation of zoledronic acid

Bibliography

• Green JR. Antitumor effects of bisphosphonates. Cancer 2003;97(3 Suppl):840-7
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Gordon S, Benford HL, Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(12 Suppl):2961-78
   PubMedGoogle Scholar
• Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9(5):745-51
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12(20):6222s-30s
   PubMed Web of Science ®Google Scholar
• Zometa. European Medicines Agency. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000336/WC500051730.pdf. [Last accessed 3 January 2011]
   Google Scholar
• Zometa. US Food and Drug Administration. Prescribing Informations. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021223s018lbl.pdf. [Last accessed 3 January 2011]
   Google Scholar
• Dunford JE, Thompson K, Coxon FP, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296(2):235-42
   PubMed Web of Science ®Google Scholar
• Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006;69(5):1624-32
   PubMed Web of Science ®Google Scholar
• Raikkonen J, Crockett JC, Rogers MJ, Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009;157(3):427-35
   PubMed Web of Science ®Google Scholar
• Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 2001;28(2 Suppl 6):4-10
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010;37(Suppl 1):S53-65
   PubMed Web of Science ®Google Scholar
• Hiraga T, Williams PJ, Ueda A, Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10(13):4559-67
   PubMed Web of Science ®Google Scholar
• Labrinidis A, Hay S, Liapis V, Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009;15(10):3451-61
   PubMed Web of Science ®Google Scholar
• Daubine F, Le Gall C, Gasser J, Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99(4):322-30
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Deux B, Monkkonen H, Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008;14(14):4658-66
   PubMed Web of Science ®Google Scholar
• Labrinidis A, Hay S, Liapis V, Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. Int J Cancer 2010;127(2):345-54
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Monkkonen H, Jones M, Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100(16):1167-78
   PubMed Web of Science ®Google Scholar
• Heymann D, Ory B, Blanchard F, Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37(1):74-86
   PubMed Web of Science ®Google Scholar
• Ory B, Moriceau G, Trichet V, Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008;12(3):928-41
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S, Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22):6538-44
   PubMed Web of Science ®Google Scholar
• Stresing V, Fournier PG, Bellahcene A, Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 2010;48(2):259-66
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S, Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-61
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Galluzzo S, Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007;13(15):4482-6
   PubMed Web of Science ®Google Scholar
• Fiore F, Castella B, Nuschak B, Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007;110(3):921-7
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Jauhiainen M, Monkkonen H, Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009;144(2):245-50
   PubMed Web of Science ®Google Scholar
• Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006;18(5):539-46
   PubMed Web of Science ®Google Scholar
• Naoe M, Ogawa Y, Takeshita K, Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 2010;18(10):493-501
   PubMed Web of Science ®Google Scholar
• Abe Y, Muto M, Nieda M, Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009;37(8):956-68
   PubMed Web of Science ®Google Scholar
• Chen T, Berenson J, Vescio R, Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42(11):1228-36
   PubMed Web of Science ®Google Scholar
• Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18(2):75-85
   PubMed Web of Science ®Google Scholar
• Skerjanec A, Berenson J, Hsu C, The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43(2):154-62
   PubMed Web of Science ®Google Scholar
• Zometa. European Medicines Agency. Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000336/WC500051691.pdf. [Last accessed 3 January 2011]
   Google Scholar
• Body JJ, Lortholary A, Romieu G, A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14(9):1557-61
   PubMed Web of Science ®Google Scholar
• Berenson JR, Vescio RA, Rosen LS, A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001;7(3):478-85
   PubMed Web of Science ®Google Scholar
• Major P, Lortholary A, Hon J, Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19(2):558-67
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7(5):377-87
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98(8):1735-44
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150-7
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100(12):2613-21
   PubMed Web of Science ®Google Scholar
• Daniele G, Giordano P, De Luca A, Anticancer effect of Bisphosphonates: new insights from clinical trials and preclinical evidence. Expert Rev Anticancer Ther 2011;11(2):299-307
   Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360(7):679-91
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Stoeger H, Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. ASCO Annual Meeting Proceedings 2010. J Clin Oncol 2010;28(15s):74S (abstract 533)
   Google Scholar
• Bundred NJ, Campbell ID, Davidson N, Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008;112(5):1001-10
   PubMed Web of Science ®Google Scholar
• Coleman R, Thorpe H, Cameron D, Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). San Antonio Breast Cancer Symposium, 2010
   Google Scholar
• Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005;10(1):52-62
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth B, Hu M, Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann NY Acad Sci 2011;1218(1):47-54
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth BB, Altundag K, Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23(6):826-36
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9(9):840
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Zoledronic acid prevents cancer treatment–induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25(7):820-8
   PubMed Web of Science ®Google Scholar
• De Luca A, Normanno N. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360(22):2368-9; author reply 9-70
   PubMed Web of Science ®Google Scholar
• Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 6 May 2011. [Epub ahead of print]
   Google Scholar